These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15361182)

  • 1. Assessing economics of treatments for gynecological cancer where clinical effectiveness meets value for money.
    Stoykova B; Dowie R; Kitchener HC
    Int J Gynecol Cancer; 2004; 14(5):762-71. PubMed ID: 15361182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health utilities in gynecological oncology and mastology in Germany.
    Hildebrandt T; Thiel FC; Fasching PA; Graf C; Bani MR; Loehberg CR; Schrauder MG; Jud SM; Hack CC; Beckmann MW; Lux MP
    Anticancer Res; 2014 Feb; 34(2):829-35. PubMed ID: 24511019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic evaluation of non-melanoma skin cancer and actinic keratosis.
    Higashi MK; Veenstra DL; Langley PC
    Pharmacoeconomics; 2004; 22(2):83-94. PubMed ID: 14731050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments.
    Aguiar PN; Adashek JJ; Roitberg F; Noia Barreto CM; Del Giglio A; Lopes GL
    Value Health Reg Issues; 2019 Dec; 20():47-50. PubMed ID: 30856543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare use among U.S. women aged 45 and older: total costs and costs for selected postmenopausal health risks.
    Hoerger TJ; Downs KE; Lakshmanan MC; Lindrooth RC; Plouffe L; Wendling B; West SL; Ohsfeldt RL
    J Womens Health Gend Based Med; 1999 Oct; 8(8):1077-89. PubMed ID: 10565666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the anesthesiologist in the wider governance of healthcare and health economics.
    Martin J; Cheng D
    Can J Anaesth; 2013 Sep; 60(9):918-28. PubMed ID: 23820969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical economics in clinical trials: the measurement of cost and outcomes in the assessment of clinical services through clinical trials.
    Schulman KA; Ohishi A; Park J; Glick HA; Eisenberg JM
    Keio J Med; 1999 Mar; 48(1):1-11. PubMed ID: 10206013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T; Dumont IP; Heinzow HS; Hutton DW
    Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using economic evaluations to reduce the burden of asthma and chronic obstructive pulmonary disease.
    Sculpher M
    Pharmacoeconomics; 2001; 19 Suppl 2():21-5. PubMed ID: 11700785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic endpoints in clinical trials.
    Cook J; Drummond M; Heyse JF
    Stat Methods Med Res; 2004 Apr; 13(2):157-76. PubMed ID: 15068259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
    Insinga RP; Ye X; Singhal PK; Carides GW
    Gynecol Oncol; 2008 Nov; 111(2):188-96. PubMed ID: 18757080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-Based Decision Making 7: Health Economics in Clinical Research.
    Manns BJ
    Methods Mol Biol; 2021; 2249():501-516. PubMed ID: 33871861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analyses and modelling the lifetime costs and benefits of health-behaviour interventions.
    Graves N; McKinnon L; Reeves M; Scuffham P; Gordon L; Eakin E
    Chronic Illn; 2006 Jun; 2(2):97-107. PubMed ID: 17175653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.